{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:35:00Z","timestamp":1795127700263,"version":"4.10.3"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023812","name":"St Vincent's Curran Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004064","name":"Prostate Cancer Research and Education Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004064","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eururo.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T01:10:18Z","timestamp":1774660218000},"page":"512-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET\/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial)"],"prefix":"10.1016","volume":"89","author":[{"given":"Sobia","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kneebone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narjess","family":"Ayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Idiare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Devitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raji","family":"Kooner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"Lieng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Rasiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Olphert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"de Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hruby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Stricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4895-7384","authenticated-orcid":false,"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.03.001_b0005","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.03.001_b0010","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2967\/jnumed.117.196683","article-title":"Treatment outcomes from 68Ga-PSMA PET\/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET","volume":"58","author":"Emmett","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.03.001_b0015","doi-asserted-by":"crossref","first-page":"794","DOI":"10.2967\/jnumed.118.220103","volume":"60","author":"Emmett","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.03.001_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109678","article-title":"Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study","volume":"184","author":"Scharl","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2026.03.001_b0025","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1200\/JCO.2023.41.16_suppl.5039","article-title":"64 Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer","volume":"41","author":"Lengyelova","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.001_b0030","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1200\/JCO.2025.43.16_suppl.5102","article-title":"COBRA: assessment of the efficacy of 64Cu-SAR-bisPSMA using histopathology and standard of care imaging as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy","volume":"43","author":"Nordquist","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.001_b0035","doi-asserted-by":"crossref","first-page":"14991","DOI":"10.1002\/anie.201908964","article-title":"A bivalent inhibitor of prostate specific membrane antigen radiolabeled with copper-64 with high tumor uptake and retention","volume":"58","author":"Zia","year":"2019","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.eururo.2026.03.001_b0040","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2025.08.005","article-title":"SPARC: the standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: A Delphi analysis","volume":"89","author":"Herrmann","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.001_b0045","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.03.001_b0050","series-title":"in men with High-Risk Features and Biochemical Failure after radical Prostatectomy: clinical Performance and Patient Outcomes","article-title":"A Prospective, Multi-site, International Comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11)","author":"Emmett","year":"2018"},{"key":"10.1016\/j.eururo.2026.03.001_b0055","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.03.001_b0060","article-title":"PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression","volume":"4","author":"Caromile","year":"2017","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.eururo.2026.03.001_b0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1084\/jem.20171052","article-title":"Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors","volume":"215","author":"Kaittanis","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.eururo.2026.03.001_b0070","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1111\/bph.13576","article-title":"The therapeutic and diagnostic potential of the prostate specific membrane antigen\/glutamate carboxypeptidase II (PSMA\/GCPII) in cancer and neurological disease","volume":"173","author":"Evans","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.eururo.2026.03.001_b0075","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.03.001_b0080","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","article-title":"[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH","volume":"39","author":"Afshar-Oromieh","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.03.001_b0085","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","article-title":"(68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","author":"van Leeuwen","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.03.001_b0090","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2967\/jnumed.117.201749","article-title":"68Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0\u00a0ng\/ml: impact on salvage radiotherapy planning","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.03.001_b0095","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","author":"Tendulkar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.03.001_b0100","article-title":"The diagnostic role of 18F-choline, 18F-Fluciclovine and 18F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: A meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2026.03.001_b0105","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2967\/jnumed.119.234898","article-title":"Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer","volume":"61","author":"Dietlein","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.03.001_b0110","first-page":"1039","article-title":"Pilot trial comparing the performance of 68Ga-PSMA-11 PET\/CT to 18F-PSMA-1007 PET\/CT in the detection of prostate cancer recurrence in men with rising PSA following radical prostatectomy","volume":"4","author":"Emmett","year":"2021","journal-title":"J Radiol Med Imaging"},{"key":"10.1016\/j.eururo.2026.03.001_b0115","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","article-title":"Prospective intra-individual blinded comparison of [(18)F]PSMA-1007 and [(68) Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer","volume":"49","author":"Pattison","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.03.001_b0120","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.119.235028","article-title":"3-year freedom from progression after 68Ga-PSMA PET\/CT-triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial","volume":"61","author":"Emmett","year":"2020","journal-title":"J Nucl Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382602035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382602035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:34:30Z","timestamp":1779917670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382602035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S030228382602035X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.001","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective Comparison of 64Copper [64Cu]SAR-bisPSMA vs 68Gallium[68Ga] PSMA-11 PET\/CT for Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy (Co-PSMA Trial)","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}